Merck Earnings: Can New Launches Offset Profit Margin Squeeze?

Merck & Company's second-quarter earnings report is set to provide crucial insights into the pharmaceutical giant's profitability pressures.

The company, which faces a portfolio transition beyond its blockbuster cancer drug Keytruda, recently launched Lipfendra, an oral PCSK9 inhibitor for lowering cholesterol, and sacituzumab tirumotecan, a TROP2-directed antibody-drug conjugate partnered with Kelun-Biotech.

Analysts expect Merck to post a loss of 29 cents per share on revenue of $16.4 billion for the quarter ended June 30, marking a sharp sequential improvement from the first quarter's $1.28-per-share loss.

The commercial rollout of newly approved products will be closely watched, particularly Lipfendra, which won FDA approval in July and is priced at $315 for a 30-day supply.

BofA Securities analysts see potential for $2 billion to $4 billion in incremental peak sales from sacituzumab tirumotecan, contingent on global development.